Shares of Danish pharmaceutical company Novo Nordisk (NOVOB.DK), known for its treatments targeting obesity and diabetes, opened slightly higher following the release of its quarterly results but quickly reversed course. As of now, the stock is down nearly 1%. Sales of Wegovy slightly exceeded market expectations, coming in at DKK 19.53 billion versus the projected DKK 19.2 billion. Novo Nordisk also unveiled a new corporate strategy focused on enhancing commercial execution and reducing costs.
- The company, which in 2024 was Europe’s most valuable publicly listed firm with a peak market capitalization of approximately $650 billion, is now facing mounting competitive pressures and legal loopholes that are enabling generic alternatives. Its market value has since dropped to roughly $212 billion.
- Despite these challenges, Novo Nordisk has reaffirmed its full-year guidance. Just days ago, the company cut its 2025 sales growth forecast, citing slower-than-anticipated expansion and deepening market headwinds. The updated projection for 2025 now stands at a reduced range of 8% to 14%, compared to the earlier outlook of 13% to 21%. This marks the second downward revision this year.
Q2 Financial Highlights
-
Revenue reached DKK 76.86 billion (~$11.92 billion), reflecting an 18% year-over-year increase, though it fell short of analyst estimates.
-
EBIT (Earnings Before Interest and Tax) came in at DKK 33.45 billion, a 29% increase compared to the same period last year.
U.S. rival Eli Lilly continues to gain ground in the weight-loss treatment space, advancing its own portfolio of GLP-1-based therapies. This growing competition has eroded Novo’s dominance and narrowed its pricing power. Although U.S. FDA regulations prohibit the replication of patented drugs, compounding pharmacies have been able to produce modified versions of Wegovy and Ozempic for custom prescriptions. These compounded alternatives, while technically legal in certain circumstances, undermine Novo Nordisk’s market exclusivity.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appStrategic Moves
Novo Nordisk has announced a revised strategic plan aimed at boosting commercial effectiveness and streamlining operational expenses. The announcement follows a turbulent week in which the company issued a profit warning and unexpectedly replaced its long-serving CEO—developments that contributed to a dramatic $95 billion drop in market capitalization.
- Maziar Mike Doustdar, a long-time executive within the company, is set to officially assume the role of CEO on Thursday. He replaces Lars Fruergaard Jorgensen, who led the company for over seven years.
- The new strategy places greater emphasis on cost discipline and operational agility, while continuing to support long-term investment in research, development, and growth initiatives.
- Sales of GLP-1 drugs Wegovy and Ozempic are increasingly threatened by compounded formulations produced by U.S. pharmacies—a workaround to existing patent protections that poses a strategic risk to Novo’s product leadership.
In a statement to shareholders, outgoing CEO Jorgensen emphasized the need to “sharpen commercial execution” and maintain financial flexibility to secure leadership in the increasingly competitive obesity and diabetes treatment market. Under new leadership, Novo Nordisk’s ability to defend its market share amid regulatory, legal, and pricing challenges will be put to the test. Investors are now awaiting clearer signals regarding Doustdar’s strategic vision and the company's next steps in navigating the volatile market ahead.
Novo Nordisk Stock (NOVOB.DK, D1 interval)
The company’s stock has declined from a high near DKK 900 to around DKK 305 today—a record plunge in its history. Behind the downturn lies intensifying competition in the GLP-1 drug segment and increasingly demanding valuation levels that the company reached in 2024. Shares currently trade at a price-to-earnings (P/E) ratio of approximately 14x, a level that may appear conservative by historical standards for Novo, but is roughly in line with the broader pharmaceutical sector average. On the other hand, at current situation, the Novo's business growth is not much faster than average for big and profitable pharma companies. On Tuesday, UBS analysts downgraded the stock to ‘neutral’, citing intensified competition. Novo is not only facing pressure from Eli Lilly’s Zepbound but also from a growing number of unofficial generic substitutes, which further undermine its position in the global market.
Source: xStation5
